NIBEC Co. Ltd - Asset Resilience Ratio

Latest as of December 2025: 2.04%

NIBEC Co. Ltd (138610) has an Asset Resilience Ratio of 2.04% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read NIBEC Co. Ltd total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

₩1.29 Billion

≈ $872.33K USD Cash + Short-term Investments

Total Assets

₩63.00 Billion

≈ $42.70 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how NIBEC Co. Ltd's Asset Resilience Ratio has changed over time. See what is NIBEC Co. Ltd's book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down NIBEC Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see NIBEC Co. Ltd (138610) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩1.29 Billion	2.04%
Total Liquid Assets	₩1.29 Billion	2.04%

Asset Resilience Insights

Limited Liquidity: NIBEC Co. Ltd maintains only 2.04% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

NIBEC Co. Ltd Industry Peers by Asset Resilience Ratio

Compare NIBEC Co. Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Fortress Biotech Inc NASDAQ:FBIO	Biotechnology	11.59%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Apellis Pharmaceuticals Inc NASDAQ:APLS	Biotechnology	0.58%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
BioArctic AB (publ) ST:BIOA-B	Biotechnology	72.35%
Chengzhi Shareholding Co Ltd SHE:000990	Biotechnology	6.73%

Annual Asset Resilience Ratio for NIBEC Co. Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for NIBEC Co. Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	2.04%	₩1.29 Billion ≈ $872.33K	₩63.00 Billion ≈ $42.70 Million	+0.87pp
2024-12-31	1.17%	₩730.00 Million ≈ $494.71K	₩62.45 Billion ≈ $42.32 Million	-7.96pp
2023-12-31	9.13%	₩6.10 Billion ≈ $4.13 Million	₩66.80 Billion ≈ $45.27 Million	-2.53pp
2022-12-31	11.66%	₩8.77 Billion ≈ $5.94 Million	₩75.20 Billion ≈ $50.96 Million	+4.64pp
2021-12-31	7.02%	₩3.74 Billion ≈ $2.54 Million	₩53.28 Billion ≈ $36.11 Million	-43.62pp
2020-12-31	50.64%	₩26.88 Billion ≈ $18.22 Million	₩53.08 Billion ≈ $35.97 Million	+23.91pp
2019-12-31	26.74%	₩9.56 Billion ≈ $6.48 Million	₩35.73 Billion ≈ $24.22 Million	+22.89pp
2018-12-31	3.85%	₩858.97 Million ≈ $582.11K	₩22.32 Billion ≈ $15.12 Million	-16.64pp
2017-12-31	20.49%	₩5.28 Billion ≈ $3.58 Million	₩25.75 Billion ≈ $17.45 Million	+0.37pp
2016-12-31	20.13%	₩4.62 Billion ≈ $3.13 Million	₩22.97 Billion ≈ $15.57 Million	--

pp = percentage points

About NIBEC Co. Ltd

KQ:138610 Korea Biotechnology

Market Cap

$198.48 Million

₩292.88 Billion KRW

Market Cap Rank

#16556 Global

#699 in Korea

Share Price

₩25900.00

Change (1 day)

-3.90%

52-Week Range

₩19320.00 - ₩52300.00

All Time High

₩55200.00